帕金森病的诊断

:,100730()50%:()()11:()21:31:11:,,(,),21:(UPDRS),31:,(PETSPECT)41:(),(Parkinsonism),[127]()11:,211:(1);(2)46Hz;(3)()()3311;21;31;41;51(70%100%);61;7155;811010(),11,;21;31();41,();511;61CT;71;81;91();1013,;111,,,,,():[127],1146Hz,70%90%,17%(PSP),29%(CBD)55%(DLBD)21,PSP,72%75%3127%56%(MSA)19%50%PSP,CBD41,PD,35%PSP87%DLBD75%MSA,1/380420066396ChinJNeurol,June2006,Vol39,No16©1994-2006ChinaAcademicJournalElectronicPublishingHouse.Allrightsreserved.:125212712GelbGJ,OliverE,GilmanS1DiagnosticcriteriaforParkinsonsdisease1ArchNeurol,1999,56:3323913GibbWRG1TheneuropathologyofParkinsonsdisease1In:JankovicJ,TolosaE,eds1Parkinsonsdiseaseandmovementdisorders1Baltimore:UrbanandSchwarzenberg,19881205222314KollerWC1HowaccuratelycanParkinsonsdiseasebediagnosed?Neurology,1992,42Suppl1:621615PaulsonHL,SternM1ClinicalManifestationsofParkinsonsdisease1In:WattsRL,KollerWC,eds1Movementdisorders1NewYork:McGraw2Hill,20041233224516HughesAJ,DanielSE,KilfordL,etal1AccuracyofclinicaldiagnosisofidiopathicParkinsonsdisease:aclinico2pathologicalstudyof100cases1JNeurolNeurosurgPsychiatry,1992,55:181218417TheGuidelineReviewPanelofNICE(thenationalinstituteforclinicalexcellence)1Diagnosisandmanagementinprimaryandsecondarycare1InParkinsonsdiseasefullguideline,secondconsultation,20061342381(:2006202208)(:):,200025(Parkinsondisease,PD),(paralysisagitans),,,1817ParkinsonPD,PD19030,10,PD,,PD,PD,,,,,,,,;;,,,,,,,PDB(MAO2B)+E(DATATOP)(9),[1],[2](DR)()Q10Q101200mg/d[3]()PD(Hoehn2Yahr)1.,,,2.(1)(1)(65),,90420066396ChinJNeurol,June2006,Vol39,No16©1994-2006ChinaAcademicJournalElectronicPublishingHouse.Allrightsreserved.